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Changes in Cytokine Production During Pregnancy in
Patients with Graves’ Disease
Brian M. Jones,1 Janette S.Y. Kwok,1 and Annie W.C. Kung2
In order to investigate the role of type 1 and type 2 cytokines in the remission of Graves’ disease (GD) during
pregnancy, spontaneous and mitogen-stimulated production of interleukin (IL)-4, IL-6, IL-10, IL-12, interferon-g
(IFN-g), and tumour necrosis factor-a (TNF-a) were measured by enzyme-linked immunospot assay of pe-
ripheral blood mononuclear cells from 10 pregnant women with GD, 8 healthy pregnant women, and 10 healthy
nonpregnant women. Tests were performed in the first, second, and third trimesters of pregnancy and 10–17
weeks after delivery. IL-4 production was not affected greatly by normal or GD pregnancy, whereas IFN-g pro-
duction was suppressed throughout pregnancy but returned to normal levels after delivery in both controls
and patients. IL-6 and TNF-a tended to be higher in GD pregnancy than normal pregnancy, especially in the
second and third trimesters. Controls had raised IL-10 in the first trimester with a return to normal levels by
the third trimester, whereas patients had raised levels throughout pregnancy. IL-12 levels were suppressed to
a greater extent in control than Graves’ pregnancy, especially during the second and third trimesters. Ratios of
IL10:IL12 in phytohemaglutinin (PHA)-stimulated cultures were much lower in GD than normal pregnancy
and cross-regulation of IL-10 and IL-12 may be deficient in GD.
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Introduction
NORMAL PREGNANCY is associated with development of atype 2 polarized cytokine profile that serves to suppress
the maternal cell-mediated antifetal immune response (1,2).
Marked increases in the levels of cortisol, estrogen, and
progesterone that occur during pregnancy appear to medi-
ate this phenomenon; glucocorticoids inhibit interleukin (IL)-
12 but not IL-10 production (3), estradiol enhances antigen-
stimulated IL-10 production in vitro (4) and progesterone
induces and enhances IL-4 production by human T cells (5).
The clinical activity of autoimmune disease frequently
changes during pregnancy. Rheumatoid arthritis, an au-
toimmune disease driven by increased production of proin-
flammatory tumour necrosis factor-a (TNF-a) (6), becomes
less active during pregnancy and flares postpartum (7), pre-
sumably because of increased levels of anti-inflammatory IL-
10. In contrast the influence of pregnancy on disease activ-
ity in women with type 2 cytokine-driven systemic lupus
erythematosus is variable, with exacerbation due to in-
creased autoantibody and immune complex formation (8) oc-
curring in at least 13% of patients (9).
There is conflicting evidence concerning cytokine polar-
ization in Graves’ disease (GD). Intrathyroidal lymphocytes
had increased expression of IL-2, IL-4, IL-10 and interferon-
g (IFN-g) (10), although large activated T cells, presumably
responsible for autoimmune damage, produced predomi-
nantly IL-4 (11). IL-2, IFN-g, TNF-a, and IL-10 but not IL-4,
messenger ribonucleic acid (mRNA) were found in in-
trathyroidal lymphocytes from GD patients in one study (12),
while another showed increased mRNA for IL-4 and IL-10
in thyroid biopsies from GD patients with high levels of anti-
thyroid antibodies (13). A recent study demonstrated com-
plementary DNA for IL-4 and IL-10, but not IFN-g, in T cells
cloned from GD thyroid tissue (14).
Phytohemagglutinin (PHA)-stimulated peripheral blood
mononuclear cells (PBMC) from untreated GD patients pro-
duced more IL-4 than normal controls (15) and ratios of IFN-
g or TNF-a to IL-4 or IL-10 were lower in GD patients than
controls (16). An enzyme-linked immunospot (ELISPOT) as-
say revealed significantly reduced IL-4 and INF-g–secreting
PBM, but normal IL-6, IL-10, IL-12, and TNF-a production
before treatment of GD patients with radioactive iodine, and
prolonged normalization of IFN-g but not IL-4 after therapy
(17). Although the evidence is somewhat conflicting, GD ap-
pears to be driven by type 2 cytokines and because IFN-g,
IL-2, and TNF-a can suppress production of antithyroid an-
tibodies by thyroid B-cells in vitro (18), GD also appears to
be regulated by type 1 cytokines. It is therefore surprising
that GD shows features of type 1 cytokine-driven autoim-
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mune diseases during pregnancy, tending to remit during
the second and third trimesters and to recur after delivery
(19). This is partially explained by a pregnancy induced
change from stimulatory to blocking autoantibody activity
(20). The studies described here indicate that there are dif-
ferences between pregnancy induced cytokine changes in
normal subjects and GD patients, most notably impaired
cross-regulation of IL12 by IL-10.
Materials and Methods
Experimental subjects
Diagnosis of GD was based on the presence of soft diffuse
goiter, raised serum free thyroxine (T4) and suppressed thy-
roid stimulating hormone (TSH). Ten pregnant GD patients
ages 30–39 (mean 32.5 6 3.1) years were studied for cytokine
production at 10–14, 21–24, and 31–35 weeks gestation and
at 10–12 weeks postpartum. Patients were receiving less than
10 mg of carbimazole or less than 100 mg of propylthiouracil
daily for the 6 months preceding conception and during
pregnancy they were given the lowest dose of drugs that
could maintain euthyroidism. All drugs were stopped by the
third trimester.
Eight healthy control pregnant women ages 30–37 (32.8 6
2.4) years were studied at 11–14, 21–24, and 30–33 weeks ges-
tation and at 11–17 weeks after delivery. Ten healthy non-
pregnant females ages 29–43 (35.8 6 4.9) were also studied.
All subjects were of Chinese ethnic origin and gave informed
consent. The study was approved by the Ethics Committee
of the University of Hong Kong.
Free T4, TSH, anti-TSH receptor antibody and cytokine
production
These were measured as described in full previously (17).
For the cytokine ELISPOT assay, which was adapted from
the method of Hagiwara et al. (21), PBMC were separated
within 60 minutes from blood taken into preservative-free
heparin by centrifugation over Lymphoprep (Nycomed,
Oslo, Norway). Multiscreen 96-well filtration plates (Milli-
pore Corp., Bedford, MA) were used for PBMC culture. IFN-
g–and IL-4–secreting cells were measured in cultures stim-
ulated with PHA (Bacto, Detroit, MI; 10 mg/mL),
concanavalin A (Con A; Sigma Chemical Co., St. Louis, MO;
20 mg/mL) and anti-CD3–coated Dynabeads (anti-CD3, Dy-
nal A.S., Oslo, Norway). IL-6, IL-10, and TNF-a–secreting
cells were measured in cultures left unstimulated or stimu-
lated with PHA, Escherichia coli 0128:B12 lipopolysaccharide
(LPS; Sigma Chemical Co.; 10 mg/mL) and Staphylococcus au-
reus Cowan I (SAC; Calbiochem, La Jolla, CA; 1:100,000). IL-
12–secreting cells were measured in unstimulated cultures
and in cultures stimulated with PHA, anti-CD3, and SAC.
All cultures were set up in duplicate and harvested after
18–22 hours at 37°C in 5% CO2.
Statistical analysis
Differences between healthy pregnant subjects and preg-
nant GD patients and between either group and nonpreg-
nant controls were analyzed by Wilcoxon signed rank test.
Regression analyses were by rank sum test. Prism version
2.0 software (GraphPad Software Inc., San Diego, CA) was
used.
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FIG. 1. Numbers of interferon-g (IFN-g)–secreting cells per million peripheral blood mononuclear cells (PBMC) in en-
zyme-linked immunospot (ELISPOT) cultures stimulated with phytohemaglutinin (PHA) (A), concanavalin A (Con A) (B)
or anti-CD3 (C). Hatched columns, normal nonpregnant controls; solid columns, pregnant controls; open columns, preg-
nant Graves’ disease (GD) patients. 1,2,3, trimester; D, postdelivery. p p , 0.05 cf. C, Wilcoxon signed rank test.
Results
At first trimester, five of the patients were still positive
for anti-TSH receptor antibody activity, suggesting active
disease, 2 of these patients had free T4 levels above the nor-
mal range (12–23 pmol/L) and four had TSH levels below
the normal range (0.35–5.5 mIU/L). Among the five pa-
tients negative for anti-TSH receptor antibody, one had free
T4 above the normal range and three had suppressed TSH
levels. Biochemical hyperthyroidism in these patients was
presumably due to raised human chorionic gonadotrophin.
Disease activity apparently moderated slightly in the sec-
ond and third trimesters, with anti-TSH receptor antibody
levels decreasing in all five positive patients, although 
one patient, who initially had low anti-TSH receptor in-
hibitory activity, became positive in the third trimester and
remained positive 12 weeks after delivery. There was no
evidence of recrudescence 10–12 weeks after delivery. All
patients had normal free T4 levels by third trimester and
one patient had biochemical relapse during the postpartum
period.
Neither IFN-g– nor IL4-secreting cells are seen in unstim-
ulated or LPS or SAC-stimulated cultures with our ELISPOT
system (22). Numbers of PHA, Con A, and anti-CD3–in-
duced IFN-g–secreting cells were lower than control values
at first, second, and third trimester in both GD and normal
pregnancy, but increased to normal after delivery (Fig. 1).
Numbers of T-cell activator-stimulated IL-4–secreting cells
were not significantly different from control values in either
normal or GD pregnancy (Fig. 2).
As shown in Figure 3, unstimulated and stimulated IL-
6–secreting cells were increased in normal pregnancy in the
first trimester, but returned to control levels thereafter. In
GD patients, IL-6 production was raised throughout preg-
nancy but fell to control levels after delivery. TNF-a–secret-
ing cells were increased in both normal and GD pregnancy
and returned to normal after delivery (Fig. 4). There were
significantly more PHA-stimulated TNF-a–secreting cells in
patients than controls at the second trimester (p 5 0.047).
IL-10–secreting cells were increased in pregnancy, but
with different kinetics in controls and GD (Fig. 5). Healthy
pregnant women had the highest increases of IL-10 produc-
tion in the first trimester, with numbers of IL-10–secreting
cells falling back to control levels by the third trimester. Un-
stimulated and PHA-stimulated IL-10 production was in-
creased maximally at second and third trimesters in GD
pregnancy (Figs. 5A and 5B), while monocyte activators LPS
and SAC induced increased IL-10 production at all three
trimesters (Figs. 5C and 5D). IL-10 returned to control levels
after delivery in both control and GD groups. There were
significantly more LPS (p 5 0.031) and SAC-stimulated (p 5
0.031) IL-10 producing cells at third trimester in GD preg-
nancy than control pregnancy.
There were also marked differences in numbers of IL-
12–secreting cells between control and GD pregnancy (Fig.
6). IL-12 production was suppressed at second and third
trimester in controls, while IL-12 was increased or normal in
GD patients at first trimester and suppressed to a much
smaller extent than controls at second and third trimester.
Controls tended to still have lower than normal IL-12 pro-
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FIG. 2. Numbers of interleukin (IL)-4-secret ing cells per million peripheral blood mononuclear cells (PBMC) in enzyme-
linked immunospot (ELISPOT) cultures stimulated with phytohemaglutinin (PHA) (A), concanavalin A (Con A) (B) or anti-
CD3 (C). See legend to Figure 1 for explanation of symbols and abbreviations.
duction at 10–12 weeks postpartum, while GD patients were
essentially normal at this time.
Figure 7 shows the ratio between IL-10– and IL-12–pro-
ducing cells, a measure of anti-inflammatory versus proin-
flammatory influences, in PHA and SAC-stimulated cul-
tures. It was not possible to determine such a ratio in un-
stimulated cultures because the majority of subjects did not
have in vivo activated IL-12–secreting cells. Ratios increased
steadily during pregnancy, indicating increasingly anti-in-
flammatory polarization of the cytokine response. In PHA-
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FIG. 4. Numbers of tumor necrosis factor-a (TNF-a)–secreting cells per million peripheral blood mononuclear cells (PBMC)
in unstimulated enzyme-linked immunospot (ELISPOT) cultures (A) and cultures stimulated with phytohemaglutinin (PHA)
(B), lipopolysaccharide (LPS) (C) or Staphylococcus aureus Cowan I (SAC) (D). See legend to Figure 1 for explanation of sym-
bols and abbreviations.
FIG. 3. Numbers of interleukin (IL)-6–secreting cells per million peripheral blood mononuclear cells (PBMC) in unstim-
ulated enzyme-linked immunospot (ELISPOT) cultures (A) and cultures stimulated with phytohemaglutinin (PHA) (B),
lipopolysaccharide (LPS) (C) or Staphylococcus aureus Cowan I (SAC) (D). See legends to Figures 1 and 2 for explanation of
symbols and abbreviations.
stimulated but not SAC-stimulated cultures, pregnant GD
patients achieved a far lower degree of type 2 polarization
at the second and third trimester than controls. Conversely,
GD patients had higher than normal SAC-induced IL-10:IL-
12 ratios at 10–12 weeks after delivery, whereas controls re-
turned to normal at this time.
Regression analysis failed to reveal a significant correla-
tion between IL10:IL12 ratios and levels of anti-TSH recep-
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FIG. 5. Numbers of interleukin (IL)-10–secreting cells per million peripheral blood mononuclear cells (PBMC) in unstim-
ulated enzyme-linked immunospot (ELISPOT) cultures (A) and cultures stimulated with phytohemaglutinin (PHA) (B)
lipopolysaccharide (LPS) (C) or Staphylococcus aureus Cowan I (SAC) (D). See legend to Figure 1 for explanation of sym-
bols and abbreviations.
FIG. 6. Numbers of interleukin (IL)-12–secreting cells per million peripheral blood mononuclear cells (PBMC) in unstim-
ulated enzyme-linked immunosport (ELISPOT) cultures (A) and cultures stimulated with phytohemaglutinin (PHA) (B),
anti-CD3 (C), or Staphylococcus aureus Cowan I (SAC) (D). See legend to Figure 1 for explanation of symbols and abbrevi-
ations.
tor inhibitory antibody (Pearson r 5 0.2801, p 5 0.080), TSH
(Pearson r 5 0.2068, p 5 0.20) or free T4 (Pearson r 5 0.0051,
p 5 0.975.).
Discussion
The study of cytokine interactions in women with au-
toimmune diseases who have become pregnant provides a
unique opportunity to examine hormonal and immunologic
influences on disease expression and greater understanding
of these interactions should yield clues to novel therapeutic
manipulations. In the present study there were both simi-
larities and differences in cytokine production between nor-
mal and GD pregnancy.
Normal pregnancy is accompanied by decreased produc-
tion of type 1 proinflammatory cytokines and increased pro-
duction of type 2 anti-inflammatory cytokines (1,2). Antigen-
and mitogen-stimulated IL-2 and IFN-g were suppressed
and IL-4 and IL-10 increased in PBMC culture supernatants,
with polarization toward type 2 cytokines increasing to max-
imum at the third trimester (23). The results presented here
indicate somewhat different kinetics when numbers of cy-
tokine-secreting cells are evaluated by ELISPOT: enhance-
ment of IL-10 production occurred in the first trimester of
normal pregnancy and decreased thereafter. Furthermore,
changes in numbers of IL-4–producing cells were relatively
minor in our study. IL-12 was suppressed to a greater extent
as pregnancy advanced and had not recovered to normal lev-
els even by 11 weeks after delivery. IFN-g was suppressed
throughout pregnancy, with different kinetics depending on
the nature of the activating stimulus. Our data suggests that
increased IL-10 and decreased IFN-g are early events in nor-
mal pregnancy and suppression of IL-12 occurs later and is
self-sustaining even when IL-10 production returns to nor-
mal.
In the present study, IL-6 was found to be elevated at first
trimester and TNF-a was increased throughout pregnancy
in controls. This is in contrast to a previous study showing
no significant changes in plasma levels of IL-6 and TNF-a
during normal pregnancy, but considerable increases asso-
ciated with preeclampsia (24). Differences in findings are
probably accounted for by different methodologies, in par-
ticular the susceptibility of measurements in plasma to in-
hibitory influences such as receptor binding (25).
Pregnant GD patients generally had similar changes in
numbers of IFN-g and IL-4–producing cells as control preg-
nant women. IL-6 production was increased in patients but
not controls at second and third trimester and TNF-a pro-
duction was higher in patients than controls at the second
trimester, when controls but not patients temporarily became
normal. These latter findings might indicate increased in-
flammatory activity during pregnancy in GD.
The clearest differences between normal and GD preg-
nancy were in IL-10 and IL-12–secreting cells. IL-10 was in-
creased throughout pregnancy in GD patients but returned
to normal by third trimester in controls. IL-12 was sup-
pressed to a much lesser extent at all times in GD pregnancy.
Because IL-10 increases preceded IL-12 decreases in normal
pregnancy it would appear that failure to suppress IL-12 pro-
duction in pregnant GD patients is because of poor responses
to apparently adequate IL-10 levels, which may have been
sustained for longer than normal because of failure to down-
regulate IL-12.
Ratios of IL-10:IL-12–secreting cells clearly showed defi-
cient type 2 cytokine polarization in GD patients at second
and third trimester in PHA-stimulated cultures, but was less
apparent using SAC activation. SAC directly stimulates IL-
12 production by monocytes, whereas PHA induces T-cells
to express CD154 that then induces IL-12 production by
monocytes via CD40 ligation (26). The latter pathway is
clearly not responsive to regulation by IL-10 in GD preg-
nancy, while the direct pathway can apparently respond nor-
mally.
Cytokine profiles of GD patients 10–12 weeks after deliv-
ery were essentially normal, which is in contrast to our pre-
vious study of patients before and after radioiodine therapy,
whose IL-4 and IFN-g production was initially deficient (17).
The pregnant patients, however, had mostly achieved dis-
ease remission prior to conception, whereas the previously
studied patients required radiotherapy for newly diagnosed
disease or disease not adequately controlled by drugs. De-
spite the differences in clinical features of the two groups,
there was also evidence from the first study that regulation
of IL-12 production by IL-10 might be deficient, because IL-
10 production was greatly increased 17 days after radioac-
tive iodine, but there was no concomitant decrease in IL-12.
Small numbers of subjects were studied here and only one
subject had highly active disease. The finding of apparently
aberrant regulation of IL-12 by IL-10 in GD should be con-
firmed in larger studies including more active patients.
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FIG. 7. Ratio of interleukin (IL)-10:IL-12– secreting cells in (A) phytohemaglutinin (PHA) and (B) Staphylococcus aureus
Cowan I (SAC)-stimulated cultures. See legend to Figure 1 for explanation of symbols and abbreviations.
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